CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the best dose of gemtuzumab ozogamicin when given together with
CPX-351 in treating patients with acute myeloid leukemia that has come back after it was
previously in remission. CPX-351 is a chemotherapy, which works in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Gemtuzumab ozogamicin is a monoclonal antibody, called
gemtuzumab, linked to chemotherapy called calicheamicin. Gemtuzumab attaches to CD33
(transmembrane receptor) positive cancer cells in a targeted way and delivers ozogamicin to
kill them. Giving CPX-351 and gemtuzumab ozogamicin may work better in treating patients with
acute myeloid leukemia, compared to giving only one of these therapies alone.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Jazz Pharmaceuticals National Cancer Institute (NCI) Pfizer University of California, Los Angeles